Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The Company's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.
Back to dashboard
Company Information
About this company
Key people
James Green
Chairman and Member of Board of Director, President, Chief Executive Officer
Steven Delmar
Chief Financial Officer, Corporate Secretary, Director
William Wilkison
Chief Scientific Officer, Director
Richard Gorman
Chief Commercial Officer
Timothy Boris
Independent Director
Peter Pieraccini
Independent Director
Ken Toombs
Independent Director
Click to see more
Key facts
- Shares in issue14.86m
- EPICVOGX
- ISINUS92859A1060
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capGBX 0.00
- Employees4
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.